RU2016146594A - Средство для лечения деменции различной этиологии - Google Patents

Средство для лечения деменции различной этиологии Download PDF

Info

Publication number
RU2016146594A
RU2016146594A RU2016146594A RU2016146594A RU2016146594A RU 2016146594 A RU2016146594 A RU 2016146594A RU 2016146594 A RU2016146594 A RU 2016146594A RU 2016146594 A RU2016146594 A RU 2016146594A RU 2016146594 A RU2016146594 A RU 2016146594A
Authority
RU
Russia
Prior art keywords
dementia
treatment
various etiologies
ethyl
etiologies
Prior art date
Application number
RU2016146594A
Other languages
English (en)
Other versions
RU2016146594A3 (ru
Inventor
Сергей Олегович Бачурин
Рахимджан Ахметджанович Розиев
Валентин Георгиевич Ненайденко
Константин Владимирович Анохин
Анна Яковлевна Гончарова
Кенес Тагаевич Еримбетов
Екатерина Валерьевна Бондаренко
Ксения Юрьевна Власова
Original Assignee
Общество С Ограниченной Ответственностью "Биофарм-Меморейн"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Биофарм-Меморейн" filed Critical Общество С Ограниченной Ответственностью "Биофарм-Меморейн"
Priority to RU2016146594A priority Critical patent/RU2016146594A/ru
Priority to EA201991337A priority patent/EA201991337A1/ru
Priority to PCT/RU2017/050122 priority patent/WO2018097768A1/ru
Priority to US16/464,283 priority patent/US20200281908A1/en
Publication of RU2016146594A publication Critical patent/RU2016146594A/ru
Publication of RU2016146594A3 publication Critical patent/RU2016146594A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Claims (1)

  1. Средство с направленной доставкой для лечения деменции различной этиологии, представляющее собой липосомальную композицию метил-4-[2-оксо-1,2-бис[[2-(4-пиридинил)этил]амино]этил]-бензоат сукцината, полученную пленочным способом с последующей гидратацией и обработкой ультразвуком.
RU2016146594A 2016-11-28 2016-11-28 Средство для лечения деменции различной этиологии RU2016146594A (ru)

Priority Applications (4)

Application Number Priority Date Filing Date Title
RU2016146594A RU2016146594A (ru) 2016-11-28 2016-11-28 Средство для лечения деменции различной этиологии
EA201991337A EA201991337A1 (ru) 2016-11-28 2017-11-28 Средство для лечения деменции различной этиологии
PCT/RU2017/050122 WO2018097768A1 (ru) 2016-11-28 2017-11-28 Средство для лечения деменции различной этиологии
US16/464,283 US20200281908A1 (en) 2016-11-28 2017-11-28 Means for treating dementia of various etiology

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2016146594A RU2016146594A (ru) 2016-11-28 2016-11-28 Средство для лечения деменции различной этиологии

Publications (2)

Publication Number Publication Date
RU2016146594A true RU2016146594A (ru) 2018-05-28
RU2016146594A3 RU2016146594A3 (ru) 2020-02-06

Family

ID=62196182

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016146594A RU2016146594A (ru) 2016-11-28 2016-11-28 Средство для лечения деменции различной этиологии

Country Status (4)

Country Link
US (1) US20200281908A1 (ru)
EA (1) EA201991337A1 (ru)
RU (1) RU2016146594A (ru)
WO (1) WO2018097768A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20220902A1 (es) * 2019-06-26 2022-05-30 Biorchestra Co Ltd Nanoparticulas micelares y sus usos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070066552A1 (en) * 2005-01-21 2007-03-22 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
RU2457205C2 (ru) * 2010-09-07 2012-07-27 Общество С Ограниченной Ответственностью "Биофарм-Меморейн" Способ, соединение и фармацевтическая композиция и лекарственное средство для восстановления утраченной памяти в норме и патологии

Also Published As

Publication number Publication date
WO2018097768A1 (ru) 2018-05-31
EA201991337A1 (ru) 2019-11-29
US20200281908A1 (en) 2020-09-10
RU2016146594A3 (ru) 2020-02-06

Similar Documents

Publication Publication Date Title
CY1124257T1 (el) N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA
EA201892128A1 (ru) Гетероциклические амиды, полезные в качестве модуляторов
EA201592212A8 (ru) Кристаллические полиморфные формы свободного основания 2-гидрокси-6-((2-(1-изопропил-1н-пиразол-5-ил)пиридин-3-ил)метокси)бензальдегида
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
CY1120454T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
DK3497081T3 (da) Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
AR103680A1 (es) Inhibidores selectivos de bace1
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
CY1124523T1 (el) Ν-[5-(αμινοσουλφονυλο)-4-μεθυλ-1,3-θειαζολ-2-υλ]-ν-μεθυλ-2-[4-(2-πυριδινυλ)-φαινυλ]-ημιενυδρη ελευθερη βαση ακεταμιδιου, μεθοδοι κατασκευης και χρησεις αυτης
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
EA201891342A1 (ru) Изоиндольные соединения
MA43685A (fr) Solutions aqueuses d'acides aminés n-acylés
DK3658547T3 (da) Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
DK3558953T3 (da) Fremgangsmåde til fremstillingen af 2-(3-(alkyl og alkenyl)morpholino)-ethan-1-oler
RU2016146594A (ru) Средство для лечения деменции различной этиологии
BR112018012095A2 (pt) formas sólidas de compostos substituidos de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina
DK3288949T3 (da) Tetrahydrofuran-fusionerede aminohydrothiazin-derivater, som er anvendelige inden for behandling af Alzheimers sygdom
PL420626A1 (pl) Nowe pochodne karbaminianów oraz ich zastosowanie
EA201891447A1 (ru) Кристаллическая форма 1,3-тиазол-5-илметил-[(2r,5r)-5-{[(2s)-2-[(метил-{[2-(пропан-2-ил)-1,3-тиазол-4-ил]метил}карбамоил)-мино]-4-(морфолин-4-ил)бутаноил-9-амино}-1,6-дифенилгексан-2-ил]карбамата или кобицистата
BR112016025244A2 (pt) uso de ácido 1,3-propanodissulfônico ou sais farmaceuticamente aceitáveis dos mesmos para o tratamento de sarcoidose.
DK3164385T3 (da) Ny polymorf form af n-[2-(6-fluor-lh-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluorpropoxy)benzylaminhydrochlorid for behandlingen af alzheimers
EP3653602A4 (en) N- (2- (NAPHTH-1-YL SUBSTITUTED) ETHYL SUBSTITUTED AMIDE COMPOUND, ITS PREPARATION AND USES
RU2013110799A (ru) Средство для профилактики и лечения диабета
RU2012134432A (ru) Антидепрессивное средство

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200824